Hepatitis A, a liver disease caused by a virus, has continued to be a primary health issue all over the world. Our company, a leader in infectious disease research, offers comprehensive hepatitis A vaccine and therapy development services.
Overview of Hepatitis A
Hepatitis A is a highly contagious disease caused by the hepatitis A virus (HAV) which is classified as a positive-sense RNA virus under the Picornaviridae family. The virus mainly targets the liver, causing inflammatory changes and a wide range of clinical features including weakness, hepatic pain, jaundice, and pyrexia. Usually, the disease spreads when the feces of an infected person is ingested by another person, or when food and beverages are contaminated. The burden of hepatitis A worldwide is still considerable, with several million cases recorded every year and particularly widespread in areas with insufficient sanitary and clean water access conditions.
Fig.1 Rates of reported acute HAV infection, by age group, in the US, 2002 to 2017. (Shouval D., et al., 2020)
Vaccine Development for Hepatitis A
The control of hepatitis A pandemics has, in particular, been facilitated by using inactivated varan viruses such as Havrix and Vaqta. These vaccines are made of inactivated HAV which elicits an immune response without causing the illness. Studies in clinics show that these vaccines are very efficacious; more than 95% of those vaccinated are protected from the disease. In one example, a comparison of data from the United States from 1996 - 2011 showed a decrease of 95% in the occurrence of hepatitis A after their active vaccination was undertaken.
Live vaccines have shown high efficacy in areas with high endemicity. For example, China began using live roughly-hepatitis a virus vaccines in 1992 as a part of the national childhood immunization program and the incidence rate started dropping. The data demonstrates that the large scale vaccination programs have greatly reduced the prevalence of hepatitis A, thus indicating the usefulness of the vaccines in managing epidemics.
Therapeutics Development for Hepatitis A
Currently, approaches focused on developing antiviral medications that limit the intensity and duration of the illness are being taken, as research continues to come up with new sore throat targeted therapies. Aminoacids had existed and could freely be experimented with and for Hepatitis A there currently is not any drug that is approved. But all of the understanding of the viral life circle will prove to be useful when working towards drug development.
Apart from the vaccine, development Our Company is also pursuing research projects aimed at finding possible therapeutics for hepatitis A. To learn more about our one-stop solutions, please click on the link below.
Our Services
As always, our support is all-encompassing, covering every aspect from the development of a hepatitis A vaccine to therapeutic agents, including protocol development and all preclinical work. The team is qualified to conduct rigorous efficacy and safety testing, ensuring that the candidate vaccines and therapeutic agents meet the necessary standards.
Disease Models
- Alb-uPA/SCID Beige Mice with Chimeric Human Livers
- Ifnar1−/− Mice
- Chimpanzees (Pan troglodytes)
- Saguinus Mystax
- Saguinus labiatus
- Owl Monkeys (Aotus species)
By integrating molecular biology, immunology, and epidemiology, our
preclinical research team conducts thorough assessments to identify promising vaccine candidates. If you are interested in our services, please feel free to
contact us.
References
- Shouval, Daniel. "The history of hepatitis A." Clinical Liver Disease 16 (2020): 12-23.
- Zhang, Li. "Hepatitis A vaccination." Human Vaccines & Immunotherapeutics 16.7 (2020): 1565-1573.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
